Skip to content

Medikidz Explain JIA Comic Book- Hebrew

Evaluating the Efficacy of a Comic Book as an Educating Tool for Children With Juvenile Idiopathic Arthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02191722
Enrollment
4
Registered
2014-07-16
Start date
2014-08-31
Completion date
2016-05-31
Last updated
2016-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis

Brief summary

We believe, that the results of this study will show that children learn from the comic book about their disease, and are now more aware and less frightened about it, and increase their compliance.

Detailed description

We believe, that the results of this study will show that children learn from the comic book about their disease, and are now more aware and less frightened about it, and increase their compliance. If so, it may promote the use of comic books or other fun educational tool in teaching children various other diseases.

Interventions

BEHAVIORALreading comics booklet

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Children with JIA aged 10-18 after parents signed ICF

Exclusion criteria

Parents that do not wanf their children to participate in the study.

Design outcomes

Primary

MeasureTime frame
30% or more improvement in a knowledge questionnaire (before and after reading the comics booklet)2 Years

Secondary

MeasureTime frame
10% or higher score in CHQ questionnaire (after reading the comics booklet)2 Years
better compliance ( >1 score improvement in 1-5 scale score, as evaluated by the physician after reading the comics booklet).2 years

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026